ImageneBio reports Q3 financial results and updates olevaprubart trial timelines
ImageneBio reported $126.6 million in cash as of Q3 2026, which funds operations into Q1 2028. The company announced top line data for its AD trial in Q4 2027 and initiated a phase 2 study in alopecia areata.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed